Photo of Jerome P. Richie,  MD

Jerome P. Richie, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6227
Fax: (617) 525-6347

Jerome P. Richie, MD

Brigham And Women's Hospital


  • Elliott Carr Cutler Professor of Surgery, Surgery, Harvard Medical School
  • Chief (Emeritus), Urology, Brigham And Women's Hospital


Research Abstract

1. Signal transduction in prostate cancer

2. Telomerase

3. Predictors of response / failure in treatment of localized prostate cancer


Powered by Harvard Catalyst
  • Richie JP. Re: Adjuvant Carboplatin Therapy in Patients with Clinical Stage 1 Testicular Seminoma: Is Long-Term Morbidity Increased? J Urol 2019. PubMed
  • Peabody JW, DeMaria LM, Tamondong-Lachica D, Florentino J, Czarina Acelajado M, Ouenes O, Richie JP, Burgon T. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial. BMC Urol 2017; 17:51. PubMed
  • Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. J Urol 2016; 197:S200-S207. PubMed
  • Saad F, Latour M, Lattouf JB, Widmer H, Zorn KC, Mes-Masson AM, Ouellet V, Saad G, Prakash A, Choudhury S, Han G, Karakiewicz P, Richie JP. Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy. J Urol 2016. PubMed
  • Martin NE, Chen MH, Zhang D, Richie JP, D'Amico AV. Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy. Clin Genitourin Cancer 2016. PubMed
  • Richie JP. Re: Trends in Testicular Cancer Survival: A Large Population-Based Analysis. J Urol 2016; 195:629. PubMed
  • Richie JP. Re: Management Trends in Stage I Testicular Seminoma: Impact of Race, Insurance Status, and Treatment Facility. J Urol 2016; 195:355. PubMed
  • Richie JP. Re: Testicular-Sparing Surgery for Bilateral or Monorchide Testicular Tumours: A Multicenter Study of Long-Term Oncological and Functional Results. J Urol 2015; 195:98. PubMed
  • Cheney MD, Zhang D, Chen MH, Loffredo MJ, Richie JP, D'Amico AV. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Clin Genitourin Cancer 2015; 13:338-43. PubMed
  • Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014. PubMed
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The effect of differing Gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clin Genitourin Cancer 2014. PubMed
  • Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum tumor diameter and the risk of prostate-specific antigen recurrence after radical prostatectomy. Clin Genitourin Cancer 2014. PubMed
  • Richie JP. Re: testicular cancer in Europe and the USA: survival still rising among older patients. J Urol 2014; 191:1293. PubMed
  • Richie JP. Re: Early development of the metabolic syndrome after chemotherapy for testicular cancer. J Urol 2014; 191:987. PubMed
  • Richie JP. Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. J Urol 2014; 191:659. PubMed
  • Richie JP. Re: dynamic contrast-enhanced subtraction MRI for characterizing intratesticular mass lesions. J Urol 2014; 191:363. PubMed
  • Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer 2014; 2014:395078. PubMed
  • Richie JP. Re: Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. J Urol 2013; 190:2096. PubMed
  • Richie JP. Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. J Urol 2013; 190:1767-8. PubMed
  • Richie JP. Re: An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy. J Urol 2013; 190:1251. PubMed
  • Richie JP. Re: A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. J Urol 2013; 190:1045. PubMed
  • Richie JP. Re: genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis. J Urol 2013; 190:537-8. PubMed
  • Richie JP. Re: Barriers to the implementation of surveillance for stage I testicular seminoma. J Urol 2013; 189:2110-1. PubMed
  • Richie JP. Re: real-time tissue elastography for testicular lesion assessment. J Urol 2013; 189:1719-20. PubMed
  • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, . Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2013; 11:594-615. PubMed
  • Richie JP. Re: clinical analysis of management of pediatric testicular germ cell tumors. J Urol 2013; 189:1532-3. PubMed
  • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M, . Bladder cancer. J Natl Compr Canc Netw 2013; 11:446-75. PubMed
  • Richie JP. Re: second malignant neoplasms in testicular cancer survivors. J Urol 2013; 189:903. PubMed
  • Richie JP. Preclinical and clinical activity of sunitinib in patients with Cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/German testicular cancer study group cooperative study. J Urol 2013; 189:533-4. PubMed
  • Richie JP. Re: Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. J Urol 2012; 189:128-9. PubMed
  • Richie JP. Re: Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. J Urol 2012; 188:2231-2. PubMed
  • Richie JP. Re: Sequelae of treatment in long-term survivors of testis cancer. J Urol 2012; 188:1771. PubMed
  • Richie JP. Re: The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. J Urol 2012; 188:1184-5. PubMed
  • Richie JP. Re: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. J Urol 2012; 188:815-6. PubMed
  • Richie JP. Re: Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Urol 2012; 188:434-5. PubMed
  • Williams SB, Hirsch MS, Kantoff PW, Richie JP. Neuroepithelial tumor arising in a testicular teratoma with retroperitoneal metastasis. J Clin Oncol 2012. PubMed
  • Richie JP. Re: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Urol 2012; 188:115-6. PubMed
  • Liong ML, Lim CR, Yang H, Chao S, Bong CW, Leong WS, Das PK, Loh CS, Lau BE, Yu CG, Ooi EJ, Nam RK, Allen PD, Steele GS, Wassmann K, Richie JP, Liew CC. Blood-based biomarkers of aggressive prostate cancer. PLoS ONE 2012; 7:e45802. PubMed
  • Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, Hu JC. Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margin(s). Urology 2010; 76:1097-101. PubMed
  • Williams SB, McDermott DW, Winston D, Bahnson E, Berry AM, Steele GS, Richie JP. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 2010; 105:918-21. PubMed
  • Williams SB, Kacker R, Steele GS, Richie JP. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy. Urol Oncol 2010. PubMed
  • Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, Richie JP, de la Rosette JJ. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010; 57:223-32. PubMed
  • Williams SB, Steele GS, Richie JP. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer. J Urol 2009; 182:2716-20. PubMed
  • Rayala HJ, Richie JP. Radical prostatectomy reigns supreme. Oncology (Huntingt) 2009; 23:863-7. PubMed
  • Williams SB,McDermott DW,Dock W,Bahnson E,Berry AM,Steele GS,Richie JP. Retroperitoneal lymph node dissection in patients with high risk testicular cancer. J Urol 2009; 181:2097-101; discussion 2101-2. PubMed
  • Prasad SM,Ferreria M,Berry AM,Lipsitz SR,Richie JP,Gawande AA,Hu JC. Surgical apgar outcome score: perioperative risk assessment for radical cystectomy. J Urol 2009; 181:1046-52; discussion 1052-3. PubMed
  • Montie JE,Clark PE,Eisenberger MA,El-Galley R,Greenberg RE,Herr HW,Hudes GR,Kuban DA,Kuzel TM,Lange PH,Lele SM,Michalski J,Patterson A,Pohar KS,Richie JP,Sexton WJ,Shipley WU,Small EJ,Trump DL,Walther PJ,Wilson TG. Bladder cancer. J Natl Compr Canc Netw 2009; 7:8-39. PubMed
  • Barrisford GW,Sartor O,Richie JP. Solitary adrenal metastatic lesion in a patient with a history of prostate cancer. Clin Genitourin Cancer 2009; 7:64-6. PubMed
  • Sommers BD,Beard CJ,D'Amico AV,Kaplan I,Richie JP,Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113:2058-67. PubMed
  • Silverman SG,Israel GM,Herts BR,Richie JP. Management of the incidental renal mass. Radiology 2008; 249:16-31. PubMed
  • Prasad SM,Keating NL,Wang Q,Pashos CL,Lipsitz S,Richie JP,Hu JC. Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy. Urology 2008; 72:647-52; discussion 652-3. PubMed
  • Richie JP. By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch? Harv Health Lett 2008; 33:8. PubMed
  • Richie JP. Impact of diagnostic delay in testis cancer: Results of a large population-based study Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility Research Group, Paule de Viguier Hospital, Toulouse University II Urol Oncol 2008; 26:220-1. PubMed
  • Richie JP. Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH, Department of Urology and Oncology, Indiana University Medical Center, Indianapolis, IN. Urol Oncol 2008; 26:218-9. PubMed
  • Richie JP. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ, Department of Urology, University of California San Francisco, San Francisco, CA. Urol Oncol 2008; 26:219-20. PubMed
  • Richie JP. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R, Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN. Urol Oncol 2008; 26:218. PubMed
  • Richie JP. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J. Department of Urology, Sidney Kimmel Center for Prostate and Urologic Urol Oncol 2008; 26:220. PubMed
  • Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008; 26:74-85. PubMed
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 2007; 110:2210-7. PubMed
  • Mukhopadhyay NK, Cinar B, Mukhopadhyay L, Lutchman M, Ferdinand AS, Kim J, Chung LW, Adam RM, Ray SK, Leiter AB, Richie JP, Liu BC, Freeman MR. The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol 2007; 21:2056-70. PubMed
  • Richie J. By the way, doctor. I heard about a new test for prostate cancer that's better than the PSA test. Should I get this test? Harv Health Lett 2007; 32:8. PubMed
  • Richie JP Jr, Komninou D, Albino AP. Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice. Int J Oncol 2007; 30:1539-43. PubMed
  • Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006; 107:2597-603. PubMed
  • Mukhopadhyay NK, Ferdinand AS, Mukhopadhyay L, Cinar B, Lutchman M, Richie JP, Freeman MR, Liu BC. Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp Cell Res 2006; 312:3782-95. PubMed
  • Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology 2006; 68:367-70. PubMed
  • Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006; 107:514-20. PubMed
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006; 5:61-6. PubMed
  • Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006; 103:6315-20. PubMed
  • Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175:907-12. PubMed
  • Silverman SG, Tuncali K, vanSonnenberg E, Morrison PR, Shankar S, Ramaiya N, Richie JP. Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients. Radiology 2005; 236:716-24. PubMed